Oklo and NuScale Power Have Shed a Combined 85.3% This Year. Why Are Nuclear Stocks Falling?

Oklo (OKLO) and NuScale Power (SMR) are down about 44% and 41%, respectively, despite a touted “nuclear renaissance” tied to AI-driven energy demand. Bank of America estimates a $10 trillion nuclear opportunity, but it does not expect real-world SMR adoption until 2030 at the earliest (meaningful adoption likely 2035–2040). The article attributes the stock weakness to risk-off investor appetite for long-dated, loss-making SMR projects, regulatory delays (Oklo not approved for construction), and ongoing shareholder dilution ahead of commercialization.

Analysis

This is a duration/financing reset more than a fundamental thesis break. When a pre-revenue infrastructure story loses market sponsorship, the stock can underperform for months even if the end-market is intact, because the equity is really pricing a sequence of permits, EPC execution, and non-dilutive financing that has not yet been de-risked. In that setup, the market usually migrates from valuing the option to valuing the cash burn, which is why small changes in rates, risk appetite, or capital-market access have outsized impact.

The second-order winner is not the other SMR developer; it is the existing power stack that can actually add megawatts today. If AI load growth is real but commercial SMR deployment slips into the 2030s, capital will rotate toward gas-fired generation, grid equipment, and independent power producers with visible cash flows. That favors names tied to immediate capacity additions and bottleneck relief, while penalizing any business model that requires years of regulatory, technical, and project-finance execution before revenue.

Contrarianly, the market may be underestimating the optionality embedded in a small float if one credible milestone lands. A project financing, utility offtake, or regulator approval could trigger a sharp squeeze because positioning is likely light and the narrative is crowded. But absent those catalysts, the burden of proof sits with the companies: every quarter of delay increases dilution risk, and that is the variable the market is now focused on, not the long-term nuclear story.

Key Decisions for Investors

• Short OKLO or SMR on strength over the next 2-6 weeks; use 3-6 month put spreads rather than outright shorts if borrow is tight. Risk/reward is attractive while the market is repricing dilution and timeline slippage; thesis is invalidated by a bankable project-finance package or regulator approval.
• Pair long XLU beneficiaries with short SMR/OKLO: long CEG or VST versus short SMR/OKLO for a 3-9 month relative-value trade. The long leg captures immediate power demand monetization; the short leg expresses the gap between narrative and cash flow.
• If expressing via options, buy 3-6 month 25-30 delta puts on SMR with a stop if the stock closes above the pre-earnings gap area on credible funding news. This is a cleaner way to monetize the market's higher probability of equity issuance before commercialization.
• Watch for a catalyst basket: NRC approval, signed offtake, or disclosed project financing. If any of those emerge, cover shorts quickly; the float is small enough that even one de-risking event can re-rate the name 20-40% in days.
• Avoid treating the weakness as a broad anti-nuclear signal. If the trade is made, isolate it to the pre-revenue SMR developers rather than the broader power or AI infrastructure complex, where the cash-flow profile is much better.